Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins

Marina Pribanić Matešić; Paola Kučan Brlić; Tihana Lenac Roviš; Željka Mačak Šafranko; Abigael Eva Chaouat; Karmela Miklić; Suzana Malić; Nina Ivanković; Maren Schubert; Federico Bertoglio; Alemka Markotić; Ofer Mandelboim; Stipan Jonjić; Ilija Brizić

doi:10.3390/v14020443

Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins

Marina Pribanić Matešić, Paola Kučan Brlić, Tihana Lenac Roviš, Željka Mačak Šafranko, Abigael Eva Chaouat, Karmela Miklić, Suzana Malić, Nina Ivanković, Maren Schubert, Federico Bertoglio, Alemka Markotić, Ofer Mandelboim, Stipan Jonjić^*, Ilija Brizić

^*Corresponding author for this work

Department of Immunology and Cancer Research

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

In early 2020, the COVID-19 pandemic sparked a global crisis that continues to pose a serious threat to human health and the economy. Further advancement in research is necessary and requires the availability of quality molecular tools, including monoclonal antibodies. Here, we present the development and characterization of a collection of over 40 new monoclonal antibodies directed against different SARS-CoV-2 proteins. Recombinant SARS-CoV-2 proteins were expressed, purified, and used as immunogens. Upon development of specific hybridomas, the obtained monoclonal antibody (mAb) clones were tested for binding to recombinant proteins and infected cells. We gener-ated mAbs against structural proteins, the Spike and Nucleocapsid protein, several non-structural proteins (nsp1, nsp7, nsp8, nsp9, nsp10, nsp16) and accessory factors (ORF3a, ORF9b) applicable in flow cytometry, immunofluorescence, or Western blot. Our collection of mAbs provides a set of novel, highly specific tools that will allow a comprehensive analysis of the viral proteome, which will allow further understanding of SARS-CoV-2 pathogenesis and the design of therapeutic strategies.

Original language	American English
Article number	443
Journal	Viruses
Volume	14
Issue number	2
DOIs	https://doi.org/10.3390/v14020443
State	Published - Feb 2022

Bibliographical note

Funding Information:
Funding: This work was supported in part by Croatian Science Foundation under the project (IP-CORONA-04-2073) and by the grant “Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology”, KK.01.1.1.01.0006, awarded to the Scientific Centre of Excellence for Virus Immunology and Vaccines and co-financed by the European Regional Development Fund.

Funding Information:
This work was supported in part by Croatian Science Foundation under the project (IP-CORONA-04-2073) and by the grant ?Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology?, KK.01.1.1.01.0006, awarded to the Scientific Centre of Excellence for Virus Immunology and Vaccines and co-financed by the European Regional Development Fund.

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

COVID-19
Monoclonal antibodies
SARS-CoV-2
Variants of concern
Spike Glycoprotein, Coronavirus/immunology
Humans
Recombinant Proteins/immunology
Antibodies, Monoclonal/classification
SARS-CoV-2/chemistry
Angiotensin-Converting Enzyme 2/genetics
Viral Proteins/antagonists & inhibitors
Antibodies, Viral/immunology
HEK293 Cells
COVID-19/therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/v14020443

Cite this

@article{58007f969d934bf99036722b77d5f08e,

title = "Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins",

abstract = "In early 2020, the COVID-19 pandemic sparked a global crisis that continues to pose a serious threat to human health and the economy. Further advancement in research is necessary and requires the availability of quality molecular tools, including monoclonal antibodies. Here, we present the development and characterization of a collection of over 40 new monoclonal antibodies directed against different SARS-CoV-2 proteins. Recombinant SARS-CoV-2 proteins were expressed, purified, and used as immunogens. Upon development of specific hybridomas, the obtained monoclonal antibody (mAb) clones were tested for binding to recombinant proteins and infected cells. We gener-ated mAbs against structural proteins, the Spike and Nucleocapsid protein, several non-structural proteins (nsp1, nsp7, nsp8, nsp9, nsp10, nsp16) and accessory factors (ORF3a, ORF9b) applicable in flow cytometry, immunofluorescence, or Western blot. Our collection of mAbs provides a set of novel, highly specific tools that will allow a comprehensive analysis of the viral proteome, which will allow further understanding of SARS-CoV-2 pathogenesis and the design of therapeutic strategies.",

keywords = "COVID-19, Monoclonal antibodies, SARS-CoV-2, Variants of concern, Spike Glycoprotein, Coronavirus/immunology, Humans, Recombinant Proteins/immunology, Antibodies, Monoclonal/classification, SARS-CoV-2/chemistry, Angiotensin-Converting Enzyme 2/genetics, Viral Proteins/antagonists & inhibitors, Antibodies, Viral/immunology, HEK293 Cells, COVID-19/therapy",

author = "Mate{\v s}i{\'c}, {Marina Pribani{\'c}} and Brli{\'c}, {Paola Ku{\v c}an} and Rovi{\v s}, {Tihana Lenac} and {\v S}afranko, {{\v Z}eljka Ma{\v c}ak} and Chaouat, {Abigael Eva} and Karmela Mikli{\'c} and Suzana Mali{\'c} and Nina Ivankovi{\'c} and Maren Schubert and Federico Bertoglio and Alemka Markoti{\'c} and Ofer Mandelboim and Stipan Jonji{\'c} and Ilija Brizi{\'c}",

note = "Funding Information: Funding: This work was supported in part by Croatian Science Foundation under the project (IP-CORONA-04-2073) and by the grant “Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology”, KK.01.1.1.01.0006, awarded to the Scientific Centre of Excellence for Virus Immunology and Vaccines and co-financed by the European Regional Development Fund. Funding Information: This work was supported in part by Croatian Science Foundation under the project (IP-CORONA-04-2073) and by the grant ?Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology?, KK.01.1.1.01.0006, awarded to the Scientific Centre of Excellence for Virus Immunology and Vaccines and co-financed by the European Regional Development Fund. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = feb,

doi = "10.3390/v14020443",

language = "American English",

volume = "14",

journal = "Viruses",

issn = "1999-4915",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "2",

}

TY - JOUR

T1 - Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins

AU - Matešić, Marina Pribanić

AU - Brlić, Paola Kučan

AU - Roviš, Tihana Lenac

AU - Šafranko, Željka Mačak

AU - Chaouat, Abigael Eva

AU - Miklić, Karmela

AU - Malić, Suzana

AU - Ivanković, Nina

AU - Schubert, Maren

AU - Bertoglio, Federico

AU - Markotić, Alemka

AU - Mandelboim, Ofer

AU - Jonjić, Stipan

AU - Brizić, Ilija

N1 - Funding Information: Funding: This work was supported in part by Croatian Science Foundation under the project (IP-CORONA-04-2073) and by the grant “Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology”, KK.01.1.1.01.0006, awarded to the Scientific Centre of Excellence for Virus Immunology and Vaccines and co-financed by the European Regional Development Fund. Funding Information: This work was supported in part by Croatian Science Foundation under the project (IP-CORONA-04-2073) and by the grant ?Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology?, KK.01.1.1.01.0006, awarded to the Scientific Centre of Excellence for Virus Immunology and Vaccines and co-financed by the European Regional Development Fund. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/2

Y1 - 2022/2

N2 - In early 2020, the COVID-19 pandemic sparked a global crisis that continues to pose a serious threat to human health and the economy. Further advancement in research is necessary and requires the availability of quality molecular tools, including monoclonal antibodies. Here, we present the development and characterization of a collection of over 40 new monoclonal antibodies directed against different SARS-CoV-2 proteins. Recombinant SARS-CoV-2 proteins were expressed, purified, and used as immunogens. Upon development of specific hybridomas, the obtained monoclonal antibody (mAb) clones were tested for binding to recombinant proteins and infected cells. We gener-ated mAbs against structural proteins, the Spike and Nucleocapsid protein, several non-structural proteins (nsp1, nsp7, nsp8, nsp9, nsp10, nsp16) and accessory factors (ORF3a, ORF9b) applicable in flow cytometry, immunofluorescence, or Western blot. Our collection of mAbs provides a set of novel, highly specific tools that will allow a comprehensive analysis of the viral proteome, which will allow further understanding of SARS-CoV-2 pathogenesis and the design of therapeutic strategies.

AB - In early 2020, the COVID-19 pandemic sparked a global crisis that continues to pose a serious threat to human health and the economy. Further advancement in research is necessary and requires the availability of quality molecular tools, including monoclonal antibodies. Here, we present the development and characterization of a collection of over 40 new monoclonal antibodies directed against different SARS-CoV-2 proteins. Recombinant SARS-CoV-2 proteins were expressed, purified, and used as immunogens. Upon development of specific hybridomas, the obtained monoclonal antibody (mAb) clones were tested for binding to recombinant proteins and infected cells. We gener-ated mAbs against structural proteins, the Spike and Nucleocapsid protein, several non-structural proteins (nsp1, nsp7, nsp8, nsp9, nsp10, nsp16) and accessory factors (ORF3a, ORF9b) applicable in flow cytometry, immunofluorescence, or Western blot. Our collection of mAbs provides a set of novel, highly specific tools that will allow a comprehensive analysis of the viral proteome, which will allow further understanding of SARS-CoV-2 pathogenesis and the design of therapeutic strategies.

KW - COVID-19

KW - Monoclonal antibodies

KW - SARS-CoV-2

KW - Variants of concern

KW - Spike Glycoprotein, Coronavirus/immunology

KW - Humans

KW - Recombinant Proteins/immunology

KW - Antibodies, Monoclonal/classification

KW - SARS-CoV-2/chemistry

KW - Angiotensin-Converting Enzyme 2/genetics

KW - Viral Proteins/antagonists & inhibitors

KW - Antibodies, Viral/immunology

KW - HEK293 Cells

KW - COVID-19/therapy

UR - http://www.scopus.com/inward/record.url?scp=85125177239&partnerID=8YFLogxK

U2 - 10.3390/v14020443

DO - 10.3390/v14020443

M3 - Article

C2 - 35216036

AN - SCOPUS:85125177239

SN - 1999-4915

VL - 14

JO - Viruses

JF - Viruses

IS - 2

M1 - 443

ER -

Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this